Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: A single-arm phase II multi-institutional study.
Jennifer L. Leddon(University of Cincinnati), Trisha M. Wise‐Draper(University of Cincinnati), Chad Zender(University of Cincinnati), Sulsal Haque(Palmetto Hematology Oncology), Yash Patil(University of Cincinnati), Vinita Takiar(University of Cincinnati), Muhammad Kashif Riaz(University of Cincinnati), Aubrey Hamilton(University of Cincinnati), Shuchi Gulati(Comprehensive Blood & Cancer Center), Sheena M Lanverman(University of Cincinnati), Misako Nagasaka(University of California, Irvine), Sarah Palackdharry(University of Cincinnati), Roman Jandarov(University of Cincinnati), Brian Cervenka(University of Cincinnati), Li Zhang(Fourth Hospital of Changsha), Alice L. Tang(University of Cincinnati), Sarah M. Wilson(University of Cincinnati), Casey Allen(University of Cincinnati), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
Cited by 5
Related Papers
A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs
|Cell stem cell|2008|4k
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Platelet Glycoprotein Ibα Is a Counterreceptor for the Leukocyte Integrin Mac-1 (Cd11b/Cd18)
|The Journal of Experimental Medicine|2000|582